EP Patent

EP4660325A2 — Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies

Assigned to Gilead Sciences Inc · Expires 2025-12-10 · 0y expired

What this patent protects

Provided are methods for identifying patient populations infected with HIV that can be targeted by antibodies that bind to HIV gp120 CD4 binding site (CD4bs) region.

USPTO Abstract

Provided are methods for identifying patient populations infected with HIV that can be targeted by antibodies that bind to HIV gp120 CD4 binding site (CD4bs) region.

Drugs covered by this patent

Patent Metadata

Patent number
EP4660325A2
Jurisdiction
EP
Classification
—
Expires
2025-12-10
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.